Recently, the first evidence for neuroprotective adjuvant therapy using Epo was provided in a murine model of cerebral malaria: an artesunate - erythropoietin drug combination led to an increase in the global survival rate compared to artesunate monotherapy and to a clinical recovery 24 hours earlier for surviving mice [69,70]. This evidence concerns the gene EPO and cerebral malaria.